You could say Invenra Inc. has been working toward bispecific antibodies for years. Founded in 2011, the University of Wisconsin-Madison spin-off launched with the aim of making antibody drug discovery more efficient, eventually developing a platform based on ultra-high-throughput technology capable of synthesizing hundreds of thousands of full-length antibodies using cell-free expression, with a screening platform that allows researchers to pinpoint those with the most promising biological activity.